Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 GlobalData Clinical Trials Report Coverage 6 Clinical Trials by Region 7 Clinical Trials and Average Enrollment by Country 8 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Five Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials 15 Clinical Trials by Phase in G7 Countries 16 Clinical Trials in G7 Countries by Trial Status 17 Clinical Trials by E7 Countries: Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials 18 Clinical Trials by Phase in E7 Countries 19 Clinical Trials in E7 Countries by Trial Status 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Subjects Recruited Over a Period of Time 25 Clinical Trials by Sponsor Type 26 Prominent Sponsors 27 Top Companies Participating in Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials 28 Prominent Drugs 29 Clinical Trial Profile Snapshots 30 Appendix 278 Abbreviations 278 Definitions 278 Research Methodology 279 Secondary Research 279 About GlobalData 280 Contact Us 280 Source 280

List of Tables Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Region, 2017* 7 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14 Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 15 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17 Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 18 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Phase, 2017* 21 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29 List of Figures Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14 Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 15 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17 Proportion of Leukocyte Disorders (White Blood Cell Disorders) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 18 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28 Leukocyte Disorders (White Blood Cell Disorders) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29 GlobalData Methodology 279

Novartis AG Merck & Co Inc Pfizer Inc Teva Pharmaceutical Industries Ltd Amgen Inc GlaxoSmithKline Plc Apotex Inc Kyowa Hakko Kirin Co Ltd Generon (Shanghai) Corp Ltd AstraZeneca Plc